Background The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis
has dramatically reduced disease in the African meningitis belt. In this context, important …

Challenges remain in developing effective meningococcal vaccines and vaccination
programs in both the industrialized and developing worlds. Vaccination programs should …

A meningococcal serogroup A polysaccharide/tetanus toxoid conjugate vaccine (P s A‐
TT)(M en A fri V ac™) is being deployed in countries of the A frican meningitis belt …

Meningococcal meningitis is an air borne disease that has affected every region of the world
for over a century now. The disease has a strong relationship with some certain factors …

Background Meningococcal meningitis is a major cause of disease worldwide, with frequent
epidemics particularly affecting an area of sub-Saharan Africa known as the “meningitis …

MenAfriVac™ is a conjugate vaccine against meningitis A specifically designed for Africa. In
Niger, the MenAfriVac™ vaccination campaign was conducted in people aged 1–29 years in …

Invasive meningococcal disease (IMD) affects approximately 1.2 million people worldwide
annually. Prevention of IMD is mostly provided through vaccination; however, no licensed …

India (481) and the lowest one was from Jordan (1). Turkish and British recorded significant
results (p= value 0.04 and 0.006, respectively) among Umrah visitors and Indian (p= value …

Neisseria meningitidis (Nm) is a major cause of bacterial meningitidis outbreaks in Africa
and the Middle East. The availability of yearly reported meningitis cases in the African …

Since it became available as a routine tool in biology, the determination and analysis of
nucleotide sequences has been applied to the design of vaccines and the investigation of …